First Commercial Implant of Endologix ALTO Abdominal Stent Graft System Done Outside the US by Drs. Andrew Holden and Andrew Hill

September 2, 2020

The first commercial implant of Endologix ALTO endograft has been completed outside of the United States, by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New Zealand.

“With the 7 mm infrarenal placement of its sealing ring, ALTO expands the endovascular treatment of AAA patients to include short and challenging aortic necks, which represent a significant portion of the underserved AAA market,” commented Dr. Holden. “We are excited to add ALTO to our endovascular armamentarium and look forward to offering this solution to a broad set of AAA patients.”

Dr. Hill added, “The ALTO endograft, with its ultra-low-profile delivery system, is ideal for treating patients with small vessels and challenging access. The new system provides a unique endovascular option, representing an important advancement for physicians and their AAA patients.”

“We are excited to commence the global roll-out of ALTO. With our planned transition to a more agile private company and our steadfast investments in clinical evidence and innovation, we are poised to meet the needs of our customers and the patients we proudly serve. ALTO offers a unique endovascular AAA treatment option and includes design features that we believe will enhance ease-of-use, improve acute outcomes, and preserve long-term durability,” commented John Onopchenko, Chief Executive Officer of Endologix.

“With both FDA approval and CE Mark, ALTO is an important therapy for physicians and their patients and yet another example of our highly differentiated portfolio of devices aimed at addressing the current unmet needs of endovascular aneurysm repair (EVAR). As we continue to execute our strategy, Endologix is committed to investing in the highest levels of clinical evidence, by initiating a head-to-head randomized controlled trial where ALTO will be compared to traditional undifferentiated EVAR grafts, with the intent of proving the superiority of ALTO. We are passionately devoted to our patient-centric mission and its ultimate goal of improving patients’ lives by enabling a single intervention to achieve the long-term durable repair. We sincerely appreciate the support of our physician partners around the globe.”

 

 

SourceEndologix
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version